ArticleBMC pulmonary medicine2025
Correlation analysis between clinical characteristics of adult patients with Mycoplasma pneumoniae pneumonia and 23S rRNA A2063 gene in alveolar lavage fluid.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Design of Ion-Pairing Azithromycin liposome for Local Pulmonary Delivery with Prolonged Lung Retention.AAPS PharmSciTech · 2026Article
- Association between 23S rRNA gene positivity and clinical characteristics in patients with mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Development and validation of a nomogram for early prediction of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the clinical features and laboratory and imaging characteristics of patients with mutations in the 23S rRNA A2063G drug resistance gene in the alveolar lavage fluid of adults with MPP.
methodsSixty-one cases of adult MPP were retrospectively analyzed. Based on the detection of the 23S rRNA A2063G resistance gene, the patients were classified into drug resistance gene-positivity (resistance group) and drug resistance gene-negative (sensitivity group) groups. The patients' general information, clinical manifestations, and relevant laboratory and chest High-Resolution Computed Tomography (chest HRCT) data were collected. The data were analyzed by t tests, rank-sum tests, chi-square tests, multifactor logistic regression analyses and other statistical methods.
resultsAmong 61 patients, 44 (72.1%) were in the resistance group, and 17 (27.9%) were in the sensitivity group. The fever rate, duration of fever and incidence of extrapulmonary complications were significantly greater in the resistance group than in the sensitivity group (P < 0.05). Fibrinogen content was significantly higher in the resistant group than in the sensitivity group (P < 0.05). Forty-two patients (95.5%) in the resistance group had imaging manifestations of centrilobular distribution, tree-in-bud sign, ground-glass opacity, and thickening of the bronchial wall, which were significantly greater than those in the sensitivity group. The difference was statistically significant (P < 0.05). Logistic regression analysis demonstrated that these imaging manifestations had a significant positive effect on the drug resistance gene-positive group.
conclusionAdults with MPP with 23S rRNA A2063G drug resistance gene mutation have more severe clinical presentations, higher serum fibrinogen levels and a greater incidence of extrapulmonary complications. Serum fibrinogen levels and imaging signs of infectious bronchiolitis are informative for the early identification of drug-resistant Mycoplasma pneumoniae in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.